Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
RTTNews
|
1081 dias atrás

(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
724 dias atrás
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
979 dias atrás
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
1006 dias atrás
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
1078 dias atrás
Bay Street May Open On Weak Note
Canadian shares may open on a weak note Monday morning, tracking lower metal prices and European stocks. However, energy stocks may find support on higher oil prices, and help limit market's downside.
RTTNews
|
2h 14min atrás
Dollar Extends Losses Amidst Powell's Dovish Surprise
A markedly dovish tone in Fed Chair Jerome Powell's speech at the Jackson Hole symposium on Friday weakened the Dollar, resulting in further losses for the currency during the week ended August 22.
RTTNews
|
2h 59min atrás
German Ifo Business Confidence Strongest Since 2024
German business sentiment hit the highest level in more than two years in August on expectations that the fiscal stimulus would help to kickstart the economic recovery. The business climate index rose to 89.0 in August from 88.6 in the previous month. This was the highest score since April 2024 and also came in above economists' forecast of 88.6. The German economy's recovery remains weak.
RTTNews
|
3h 2min atrás
CAC 40 Down Nearly 0.6% In Cautious Trade
French stocks remain in negative territory on Monday, with investors mostly making cautious moves, looking for some more clarity on U.S. - EU trade deal, and awaiting crucial inflation data from the region.
RTTNews
|
3h 36min atrás